# A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors

> **NCT06007482** · PHASE1 · COMPLETED · sponsor: **Elpiscience Biopharma Australia Pty. Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** ES009

## Key facts

- **NCT ID:** NCT06007482
- **Lead sponsor:** Elpiscience Biopharma Australia Pty. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-26
- **Primary completion:** 2025-02-18
- **Final completion:** 2025-02-18
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06007482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06007482, "A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06007482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*